Healthcare
Radiopharm Theranostics Limited(RADX)
Live Price
Offline$4.27
-2.73% today
1Y Change
-2.73%
Window
Jun 23, 2025 → Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +1114.3%
- EPS Growth
- +85.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Radiopharm Theranostics Limited (RADX) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $4.27 and down 2.7% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +1114.3%, EPS growth of +85.3%, a dividend yield of 0.0%. What stands out right now is revenue +1114.3%, EPS +85.3%, free cash flow -59.5% with operating margin -1050.6% and ROIC -53.4%. Valuation is more restrained than many high-expectation growth names at price/sales 2.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RADX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1114.3% vs +7.6% peer median
Operating Margin
Below sector median
-1050.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +1114.3% and EPS at +85.3%, with operating margin around -1050.6%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RADX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RADX Max Drawdown
-62.37%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RADX and SPY.
Company Overview
Radiopharm Theranostics Limited
NASDAQ Capital Market
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
- Leadership
- Riccardo Canevari
- IPO Date
- Dec 5, 2024
- Employees
- 14
- Street Address
- 62 Lygon Street
- Mailing
- Carlton, VIC, 3053
- Region
- Carlton, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9824 5254
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.6
- Price/Sales
- 2.2
- Price/Book
- 0.9
Growth
- Revenue
- +1114.3%
- EPS
- +85.3%
- Free Cash Flow
- -59.5%
Profitability
- Gross Margin
- 1.1%
- Operating Margin
- -1050.6%
- Net Margin
- -1055.3%
- ROE
- -105.2%
- ROIC
- -53.4%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 2.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.